A number of therapies are beneficial in the management of patients with acute myocardial
infarction (MI), including revascularization with either percutaneous coronary intervention or …

Background There are few data on the comparative effectiveness of angiotensin II receptor
blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs) in a broad spectrum …

Coronary artery diseases (CADs) are preventable and controllable disorders, but they
continue to be a major cause of morbidity and premature mortality across globe. India is …

There is strong evidence from controlled clinical trials that in the setting of acute myocardial
infarction complicated by heart failure or isolated left ventricular dysfunction, angiotensin …

Besides reperfusion treatment, which is the most powerful approach to the underlying
pathophysiological cause of myocardial infarction, adjunctive therapies should be …

Approximately 50% of patients recovering from acute myocardial infarction have significant
left ventricular systolic dysfunction and could benefit considerably from the long-term …

The purpose of the present article was to review the current evidence on the use of
angiotensin-converting enzyme (ACE) inhibitors in acute myocardial infarction (MI). This …

Angiotensin‐converting enzyme inhibitor therapy has been shown to be effective in treating
patients across the spectrum of cardiac disease. Utility has been demonstrated for both …

Which patients with an acute myocardial infarction should be treated with an angiotensin-
converting enzyme (ACE) inhibitor and when should this treatment be initiated? Combining …

Beta-blockers, angiotensin-converting–enzyme (ACE) inhibitors, and aldosterone
antagonists have been shown to reduce the overall risk of death as well as the risk of major …